Study of ARO-RAGE in Healthy Subjects

Asthma Clinical Trial

Official title:

A Phase 1 Study Evaluating the Effects of ARO-RAGE Injection for Subcutaneous Administration in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05533294
• Other study ID #: ARORAGE-1002
• Status: Completed
• Phase: Phase 1
• Start date: November 29, 2022
• Est. completion date: February 8, 2024

Study information

• Verified date: August 2023
• Source: Arrowhead Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-RAGE Injection in normal healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: February 8, 2024
• Est. primary completion date: February 8, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Normal pulmonary function tests at Screening prior to sputum induction

• Normal 12-lead electrocardiogram (ECG) at Screening

• Non-smoking

• Able to produce an induced sputum sample at Screening

• Participants of child-bearing potential (male and female) must use highly effective contraception and cannot donate sperm or eggs during the study or for at least 12 weeks following the end of the study or last dose of study drug, whichever is later. Women must have a negative pregnancy test and cannot be breastfeeding

• Willing to provide written informed consent and to comply with study requirements

Exclusion Criteria:

• Acute lower respiratory infection within 30 days prior to first dose and/or acute upper respiratory infection within 7 days prior to first dose

• Positive COVID-19 test during Screening window

• Chronic or acute infection that is clinically significant or requires treatment with systemic antibiotics, antivirals, antifungals, or antiparasitics within 30 days prior to first dose

• Any history of chronic pulmonary disease

• Use of immunosuppressive medication within 90 days prior to first dose

• Receipt of any intranasal vaccine within 30 days prior to first dose

• Human Immunodeficiency virus (HIV) infection, seropositive fo Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)

• Uncontrolled hypertension

• Use of illicit drugs

• Unwilling to limit alcohol consumption to within moderate limits for the duration of the study

• Use of an investigational agent or device within 30 days prior to first dose

• Prior use of any formulation of ARO-RAGE

Note: additional inclusion/exclusion criteria may apply per protocol

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• ARO-RAGE Injection
ARO-RAGE injection for sc administration
• Placebo
normal saline (0.9% NaCl) by sc injection

Locations

Country	Name	City	State
New Zealand	Research Site	Grafton	Aukland

Sponsors (1)

Lead Sponsor	Collaborator
Arrowhead Pharmaceuticals

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Treatment-Emergent Adverse Events (TEAEs)		From first dose of study drug through the end of study (EOS; up to 113 days or until serum soluble receptor for advance glycation end products [SRAGE] is =70% of baseline value, whichever is later)
Secondary	Change from Baseline Over Time in Forced Expiratory Volume (FEV1)		Baseline through EOS (up to 113 days or until serum SRAGE is =70% of baseline value, whichever is later)
Secondary	Change from Baseline Over Time in Forced Vital Capacity (FVC)		Baseline through EOS (up to 113 days or until serum SRAGE is =70% of baseline value, whichever is later)
Secondary	Change from Baseline Over Time in Diffusing Capacity for Carbon Monoxide (DLCO)		Baseline through EOS (up to 113 days or until serum SRAGE is =70% of baseline value, whichever is later)
Secondary	PK of ARO-RAGE: Maximum Observed Plasma Concentration (Cmax)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29
Secondary	PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to 24 Hours (AUC0-24)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29
Secondary	PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to the Last Quantifiable Plasma Concentration (AUClast)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29
Secondary	PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to Infinity (AUCinf)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29
Secondary	PK of ARO-RAGE: Terminal Elimination Half-Life (t1/2)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29
Secondary	PK of ARO-RAGE: Apparent Systemic Clearance (CL/F)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29
Secondary	PK of ARO-RAGE: Apparent Terminal-Phase Volume of Distribution (VZ/F)		single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29